FNCT Biotech
PrivateLast Round
Series B
Jun 16, 2026
Total Funding Raised
$18.15M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
FNCT Biotech operates in Healthcare & Life Sciences and is based in South Korea. Its latest recorded funding round was a Series B round in June 2026.
FNCT Biotech is a biotechnology company that develops first-in-class antibody therapeutics for diseases with high unmet medical needs, particularly Idiopathic Pulmonary Fibrosis (IPF) and various cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
FNCT Biotech Comparables
Compare FNCT Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pulmongene | 80% | |
| PureTech Health | 76% | |
| Oorja Bio, Inc. | 75% |
For institutional investors. Book with your work email.
FNCT Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 16, 2026 | ||||
| Series A | Jan 20, 2025 | ||||
| Seed | Jul 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
FNCT Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DAYLI Partners | Seed |
| Premier Partners | Series B |
| BSK Investment | Series B |
| IBK Capital | Series B |
| NICE Investment Partners | Series B |
| NH Nonghyup Bank | Series B |
| Solidus Investment | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 13, 2026
Monthly visitors increased 148% MoM, reaching 4.4K.
- Sep 11, 2026
Monthly visitors increased 1280% MoM.
For institutional investors. Book with your work email.
FNCT Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about FNCT Biotech's valuation, stock price, and market status.
Is FNCT Biotech a public or private company?
FNCT Biotech is a private company.
What is the current stock price of FNCT Biotech?
FNCT Biotech is a private company, so its shares have no public market price. Caplight tracks FNCT Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is FNCT Biotech worth (valuation)?
Valuation information for FNCT Biotech is not publicly available.
Can I buy FNCT Biotech stock?
FNCT Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was FNCT Biotech's last funding round?
FNCT Biotech's most recent funding round was Series B on June 16, 2026.
Who are the main investors in FNCT Biotech?
Key investors in FNCT Biotech include Premier Partners.
Will FNCT Biotech IPO soon?
No public IPO plans have been announced for FNCT Biotech.
How can I track FNCT Biotech secondary market activity?
Caplight tracks bids, offers, and trades in FNCT Biotech's shares on secondary markets.